Unclassified four-repeat tauopathy associated with familial parkinsonism and progressive respiratory failure

Masayoshi Nakano1†, Yuichi Riku2†, Kenya Nishioka3, Masato Hasegawa4, Yukihiro Washimi1, Yutaka Arahata1, Akinori Takeda1, Kentaro Horibe1, Akiko Yamaoka1, Keisuke Suzuki1, Masashi Tsujimoto1, Yuanzhe Li3, Hiroyo Yoshino5, Nobutaka Hattori3,5, Akio Akagi2, Hiroaki Miyahara2, Yasushi Iwasaki2 and Mari Yoshida2*

Abstract
We describe an autopsied patient with familial parkinsonism and unclassified four repeat-tau (4R-tau) aggregation. She presented with bradykinesia, truncal dystonia, and mild amnesia at the age of 61 and then exhibited body weight loss (15 kg over 8 months), sleep disturbances, and progressive respiratory failure with CO2 narcosis. She died of respiratory failure at the age of 62, 14 months after disease onset. Her brother also showed parkinsonism at the age of 58 and suddenly died 6 months later. Postmortem examination revealed 4R-tau aggregation, which was characterized by neuronal globose-type tangles or pretangles, bush-like or miscellaneous astrocytic inclusions, and coiled bodies. The temporal tip, the striatum, the substantia nigra, the tegmentum of the midbrain, the medullary reticular formation, and the spinal cord were severely involved with tau aggregation. Argyrophilic grains and ballooned neurons were also found in the medial temporal structures, however, extensions of the 4R-aggregations in the case were clearly broader than those of the argyrophilic grains. Western blot analysis of sarkosyl-insoluble fractions from brain lysates revealed prominent bands of tau at both 33 kDa and 37 kDa. Genetic examinations did not reveal any known pathogenic mutations in MAPT, DCTN1, PSEN1, or familial or young-onset parkinsonism-related genes. The clinical manifestations, pathologic findings, and biochemical properties of aggregated tau in our patient cannot be explained by argyrophilic grain disease or other known 4R-tauopathies alone. Our results further extend the clinical and neuropathologic spectra of 4R-tauopathy.

Keywords: Four-repeat tau aggregation, Familial parkinsonism, Respiratory failure, Autopsy, Postmortem study

Introduction
Neuronal and glial aggregation of tau protein is known to cause neurodegenerative diseases. Tau protein is classified into three-repeat tau (3R-tau) and four-repeat tau (4R-tau), which are determined by alternative mRNA splicing of exon 10 [1, 10]. Aggregations of 4R-tau are pathologic hallmarks of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain dementia (AGD), globular glial tauopathy (GGT), aging-related tau astrogliopathy (ARTAG), and microtubule-associated protein tau (MAPT) gene mutation-associated familial frontotemporal dementia (FTD) and parkinsonism, whereas neuronal inclusions of 3R-tau are characteristic of Pick’s disease (PiD) [17, 19, 21].

In this report, we describe a patient who presented with progressive parkinsonism, body weight loss, and respiratory failure. Her sibling showed similar clinical manifestations. The proband died 14 months after disease onset,
and a postmortem study revealed severe 4R-tau aggregation, which could not be classified into known disease entities.

Case presentation

Medical history

The proband was a Japanese female (shown as II-2 in Fig. 1a). She had been diagnosed with depression at the age of 50 and recovered at the age of 52 without any medications. At the age of 61, she presented with gait disturbance, dropped head, and amnesia and visited the hospital 6 months after disease onset. Our neurological examinations revealed supranuclear gaze palsy upward, rigidity in the truncus and limbs, clumsiness from diadochokinesis, anteropulsion, masked face, and small voice speech. Limb ataxia and tremor were not observed. Hyperreflexia was observed in the bilateral upper limbs. The Mini-Mental State Examination score was 24 of 30; six points were subtracted from the score in the calculation and recall sections. The indices related to cognitive decline showed 6 of 70 on the Alzheimer's disease assessment scale-cognitive subscale, 32 of 36 on Raven's colored progressive matrices test, and 16 of 18 on the frontal assessment battery. All scores were within normal ranges. Brain magnetic resonance images revealed mild atrophies in the midbrain, hippocampus, and anterior portion of the temporal lobe (Fig. 1b). Brain single photon emission computed tomography indicated decreased blood flow in the anterior and medial regions of the left temporal lobe (Fig. 1c). The radioactivity of the bilateral putamen on dopamine transporter scintigraphy (Fig. 1d) was depleted. Meta-iodobenzylguanidine myocardial scintigraphy showed slight depletion of intake (the heart to mediastinum ratios, of which the cutoff value was 2.0, were 1.86 and 1.85 at the early and late registrations, respectively). We made a diagnosis of Parkinsonian syndrome and administered levodopa/benserazide and increased the dose up to 450 mg/day.

Fig. 1 Clinical overview of the patients who presented with parkinsonism and progressive respiratory failure. a Our patient is shown as the proband (II-2) with an arrow. Patients with parkinsonism are shown as a filled circle or square for the proband and her elder brother (II-1), respectively. Her fourth (III-4) and fifth (III-5) children were conjoined twins and aborted before being delivered. Oblique lines indicate death. b T1- and T2-weighted brain magnetic resonance images (Siemens Magnetom Skyra 3.0 T) show mild atrophy in the midbrain, hippocampus, and temporal lobes, where marked with arrows. c $^{123}$-IMP brain single photon emission computed tomography indicates decreased blood flow in the anterior and medial regions of the left temporal lobes as marked with arrows. d The radioactivity in the bilateral putamen of dopamine transporter scintigraphy is depleted and is depicted as dot-like shapes (the specific binding ratio values using the Tossici-Bolt method were 1.72 for the right striatum and 1.62 for the left striatum). Abbreviations: T1WI, T1-weighted brain magnetic resonance images; T2WI, T2-weighted brain magnetic resonance images; A, anterior; P, posterior; R, right; L, left.
was no obvious improvement, and she gradually became less active. Fourteen months after disease onset, she was brought to our hospital. She presented with 15 kg of weight loss since the first visit, drowsiness, cyanosis of the limbs, and myoclonus of the upper limbs. Blood examination revealed secondary polycythemia. Arterial blood gas analysis showed hypercapnia and respiratory acidosis (pH 7.33, pO2 28.8 mmHg, pCO2 90.9 mmHg, base excess extracellular fluid 20.8 mmol/l, HCO3− 46.7 mmol/l). She was admitted to the hospital and died of respiratory failure at the age of 62 on the fourth day of admission.

Her elder brother, who is shown as II-1 in Fig. 1a, also presented with parkinsonism, including gait disturbance, masked face, and bradykinesia, at the age of 58. He refused to undergo any diagnostic imaging and was suspected to have Parkinson's disease according to his symptoms. He died at home 6 months after he first visited our hospital. Her second child, who is shown as III-2 in Fig. 1a, has suffered from depression for 6 years. There was no consanguinity in the family.

Protocols for neuropathologic, biochemical and genetic analyses
Written informed consent for a postmortem study and genetic analysis was obtained from the patient's family in compliance with the ethical committee for medical research of Aichi Medical University and Juntendo University, Japan.

The left hemisphere was fixed in 20% formaldehyde for 2 months, embedded in paraffin, and then sectioned into 5 μm thick sections. Hematoxylin and eosin staining, Klüver-Barrera staining, and Gallyas-Braak staining were performed. Primary antibodies for immunohistochemistry were as follows: anti-hyperphosphorylated tau (AT8, mouse monoclonal, 1:3000, Innogenetics, Ghent, Belgium), anti-3R-tau (RD3 8E6/C11, mouse monoclonal, 1:500, Upstate, Lake Placid, NY), anti-4R-tau (RD4 1E1/A6, mouse monoclonal, 1:500, Upstate), anti-phosphorylated TAR DNA binding protein 43 kDa (pTDP-43 C-terminal fragment of tau protein).

Tissue lysates of the frozen right prefrontal cortex and caudate nucleus were subjected to western blotting using anti-AT8 and anti-T46 (Thermo Fisher) antibodies, as we described previously [2, 30]. Brain lysates taken from patients with CBD (a male patient who died at the age of 73) and PSP (a male patient who died at the age of 63) were also assessed for comparison. Tau fibrils obtained from sarkosyl-insoluble fractions were analyzed with immune electron microscopy using anti-AT8 antibody and anti-tau C antibody that we generated to label the C-terminal fragment of tau protein.

Gene sequencing analyses were performed at the department of neurology, Juntendo University. We extracted DNA from peripheral blood with a standard protocol. Next, we screened the genes related to Perry syndrome, frontotemporal dementia (FTD), such as DCTN1, and MAPT by Sanger sequencing and C9orf72 by the repeat-primed PCR. The technological details and the protocols for MAPT, DCTN1, and C9orf72 were described in previous reports [6, 13, 27]. Other genes related to familial or Parkinson's disease, parkinsonism, and Alzheimer's disease, including SNCA, PRKN, UCHL1, PINK1, DJ-1, LRRK2, ATP13A2, GIGYF2, HTRA2, PLA2G6, FBXO7, VPS35, EIF4G1, DNAJC6, SYN1, DNAJC13, CHCHD2, GCH1, NIA4A, VPS13C, RAB7L1, BST1, C19orf72, RAB39B, PSEN1, GRN, APP and APOE, were screened by the targeted gene panel sequence with an Ion Torrent System (Thermo Fisher Scientific, Waltham, MA, US). The details of methods are reported previously [11]. The targeted variants were confirmed by Sanger sequencing. The panel for sequencing was designed in Ion AmpliSeq Designer [33]. Library preparation was performed using an Ion AmpliSeq Kit for Chef DL8 and an Ion Chef System. Emulsion polymerase chain reaction was performed using an Ion 530 Kit-Chef. The sequences were obtained on an Ion 530 Plus Sequencer using an Ion 530 Chip. Sequence alignment was performed using the Torrent Mapping Alignment Program implemented in v5.10 of Torrent Suite software (Thermo Fisher Scientific).

Neuropathologic findings
The brain weighed 1260 g before a fixation. The temporal tip and the hippocampus were mildly atrophied. The tegmentum of the brainstem, the medullary recticular formation, and the fasciculus anterolateralis of the spinal cord showed marked atrophy. The substantia nigra showed severe discoloration, whereas the locus coeruleus was retained. The cerebral neo- cortices, basal ganglia, and cerebellum were not atrophied (Fig. 2a–g). Microscopically, neuronal loss and astroglialosis were prominent in the temporal tip, amygdala, ambient gyrus, and substantia nigra (Fig. 2h–i).
Occasional ballooned neurons were observed in those regions and in the anterior horn of the spinal cord (Fig. 2j, k). Immunohistochemistry revealed AT8- and RD4-immunopositive neuronal and glial inclusions to be abundant in the temporal tip, amygdala, CA1, subiculum, ambient gyrus, substantia nigra, tegmentum of the midbrain, reticular formation of the medulla oblongata, hypoglossal nerve nucleus, and anterior horn of the spinal cord (Fig. 3a–e). The neuronal inclusions were globose-type tangles or pretangles (Fig. 3f–g), and a subset of neuronal inclusions in the spinal anterior horn showed fine, fibrous configurations (Fig. 3h). The astrocytes demonstrated miscellaneous aggregations of hyperphosphorylated tau; bush-like granular or thorn-shaped dense aggregations within the proximal or distal portions of the foot processes were observed (Fig. 3i–k). Coiled bodies, which represented oligodendrocytic aggregations of hyperphosphorylated tau, were observed in the white matter (Fig. 3l). These glial 4R-tau aggregations were fundamentally argyrophilic
RD3 immunostaining was negative in most regions. Typical tufted astrocytes, astrocytic plaques, or globular glial inclusions were not observed. Argyrophilic grains were observed in the entorhinal cortex, the ambient gyrus, the subiculum, and the CA1, corresponding to stage III of Saito’s grading (Fig. 3n) [29]. Anti-phosphorylated TDP-43 immunohistochemistry revealed occasional dot-like aggregations within the neuronal cytoplasm in the hippocampus and the gray matter of the brainstem. Mislocalization of TDP-43 from the nuclei was not observed. Mild deposition of beta-amyloid was found in the frontal cortex, corresponding to Thal’s phase 1 [31] and grade A of the Consortium to Establish a Registry for Alzheimer’s Disease [24]. Anti-alpha-synuclein immunohistochemistry was negative in the brain, spinal cord, and pericardial sympathetic nerves. The hippocampal pyramidal neurons show argyrophilic grains (n). Anti-AT8 immunohistochemistry, anti-RD4 immunohistochemistry, and Gallyas–Braak staining were used. Scale bars: a–d 100 µm, e, j, k 20 µm, f–i, l–n 10 µm.

**Fig. 3** Tau-immunopositive inclusions. Anti-AT8 immunohistochemistry reveals prominent neuronal and astrocytic aggregations in the deep layer of the cerebral cortex (a). Tau aggregation is also severe in the medullary reticular formation (b) and the anterior horn of the spinal cord (c). The intramedullary tract of the hypoglossal nerve shows intraaxonal tau aggregation (d). The tau aggregations were four-repeat tau-immunopositive (a). The neuronal inclusions comprised globose-type neurofibrillary tangles (f) and pretangles (g), and a subset of the motor neurons in the spinal anterior horn show tau inclusions with fine, fibrous configurations (h). The astrocytes demonstrate miscellaneous aggregations, including bush-like inclusions (i), and depositions within the distal (j) and proximal foot processes (k). Oligodendroglial inclusions are abundant in the cerebral white matter (l). Astrocytic inclusions are fundamentally argyrophilic (m). The hippocampal pyramidal neurons show argyrophilic grains (n). a–d, f–l Anti-AT8 immunohistochemistry, e anti-RD4 immunohistochemistry, and m, n Gallyas–Braak staining were used. Scale bars: a–d 100 µm, e, j, k 20 µm, f–i, l–n 10 µm.
did not show myogenic atrophies, internal nuclei, or ring fibers. The systemic organs showed no remarkable lesions causative of respiratory failure and death.

Double immunofluorescence for AT8 combined with TH, TrOH, or ChAT was performed to assess tau aggregation within the neurons of the ventrolateral medullary (VLM) nucleus, raphe nucleus, or nucleus ambiguus, respectively, of the medullary reticular formation [28]. The fluorescent signal of AT-8 was more prominently colocalized with ChAT in the nucleus ambiguus than with TH in the VLM nucleus or TrOH in the raphe nucleus (Fig. 4a–i). AT-8-immunopositive neurons occasionally contained dot-like aggregations of phosphorylated TDP-43 (Fig. 4j–l). The distributions of neuronal and glial tau aggregations are summarized in Table 1.

### Outcomes of western blot

Anti-tau (T46) immunoblot of sarkosyl-insoluble fractions from the frontal cortex and striatum revealed major doublets at 64 and 68 kDa and bands at 33 and 37 kDa. The blotting bands at 33 kDa and 37 kDa were equally prominent. These blotting patterns were different from those of PSP or CBD, which would be characterized by a prominent band at either 33 kDa or 37 kDa, respectively [2] (Fig. 5a).

### Outcomes of immunoelectron microscopy

Tau fibrils, which were isolated from the sarkosyl-insoluble fraction, had diameters of 15–20 μm and exhibited long periodicity and immunoreactivity to anti-AT8 and anti-tau C terminal antibodies (Fig. 5b, c).

### Table 1 Distributions of neuronal and glial tau aggregations

| Regions                        | NI | Grain | Glial inclusions |
|--------------------------------|----|-------|------------------|
| Frontal cortex                 | +  | −     | +                |
| Primary motor cortex           | ++ | −     | +                |
| Temporal cortex                | +  | +*    | +                |
| Insula                         | ++ | −     | +                |
| Subiculum/CA1                  | ++ | ++    | +                |
| CA2-4                          | +  | ++    | +                |
| Dentate gyrus                  | +  | −     | +                |
| Parahippocampal cortex         | ++ | +++   | +                |
| Amygdala                       | ++ | +     | +                |
| Temporal tip                   | ++ | −     | +                |
| Parietal cortex                | +  | −     | +                |
| Occipital cortex               | +  | −     | +                |
| Neostriatum                    | ++ | −     | +                |
| Globus pallidus                | ++ | +     | +                |
| Basal nucleus of Meynert       | ++ | −     | +                |
| Cerebral white matter          | −  | −     | +                |
| Pars reticulata of substantia nigra | ++ | −     | +                |
| Pars compacta of substantia nigra | +  | −     | +                |
| Tegmentum of midbrain          | ++ | −     | +                |
| Locus ceruleus                 | +  | −     | +                |
| Pontine nucleus                | +  | −     | +                |
| Medullary reticular formation  | ++ | −     | +                |
| Anterior horn of spinal cord   | ++ | −     | +                |
| Dorsal horn of spinal cord     | +  | −     | +                |

−, negative; +, mild; ++, severe; NI, neuronal inclusions; *, only in the occipitotemporal gyrus.
Outcomes of genetic analysis
There were no known pathogenic or rare variants in the causative genes related to Perry syndrome, FTD, familial Parkinson's disease, parkinsonism, or Alzheimer's disease.

Discussion and conclusions
The patient died of respiratory failure 14 months after the presentation of parkinsonism. A postmortem study revealed neuronal and glial aggregation of 4R-tau. Tau aggregations and neuronal loss were prominent in the medial temporal lobes, the temporal tip, the striatum, the substantia nigra, the tegmentum of the midbrain, and the medullary reticular formation. Astrocytic inclusions comprised granular or dense aggregations of the proximal or distal portion of the foot processes; the morphological features were similar to those of the bush-like or thorn-shaped astrocytes in ARTAG [19]. Oligodendroglia showed the appearance of coiled bodies but not globular glial inclusions [17]. Western blot analysis of the sarkosyl-insoluble fraction revealed a low molecular band equally prominent at 33 and 37 kDa [2]. On electron microscopy, the aggregated tau fibrils were relatively straight with long periodicity, which was similar to those in PSP and CBD [3]. These clinical findings, morphological and biochemical findings of tau aggregations, and distributions of tau aggregations and neuronal loss could not be classified into known 4R-tau-related neurodegenerative disorders, including PSP, CBD, GGT, ARTAG, and AGD.

Her sibling also showed rapidly progressive parkinsonism and sudden death. Unfortunately, a postmortem study was not undertaken for him, and it was unclear if he also had 4R-tau aggregation. However, the familial clustering of neurological manifestations suggests a genetic background. We did not identify pathologic mutations in MAPT or DCTN-1, which are causative of familial tauopathy and Perry syndrome, respectively [6, 12]. The other genetic variants related to parkinsonism and cognitive disorders were also not detected either. We could not evaluate the possibility of a novel gene by whole genome sequencing or linkage analysis due to the small number of family members. We expect further investigation to find any novel gene variants, which characterize this unclassifiable 4R-tauopathy with clinically aggressive manifestations and the chance of familial history.

Sporadic or familial patients with unclassifiable 4R-tau aggregations have occasionally been reported [4, 7, 15, 16].
Although gene variants in MAPT or FUS have been suggested, the pathogenesis remains unclear [7, 18]. FTD, parkinsonism or both have been observed in previous reports. Important clinical features of our patient were nonmotor symptoms of progressive respiratory failure with hypercapnia, weight loss, and sleep disturbance. The postmortem assay revealed prominent aggregations of tau in the medullary reticular formation, particularly in the nucleus ambiguous. The region is known as a part of the ventral respiratory group and as a parasympathetic center. Its pathologic involvement might contribute to those nonmotor symptoms, as presumed for the autonomic dysfunctions of Perry syndrome [26]. Another finding of interest was severe tau aggregations in the lower motor neurons of the spinal cord. A subset of neuronal inclusions showed AT-8-immunopositive fibrous configurations that differed from pretangles or globosetypetangles. The skeletal muscles did not show neurogenic atrophy, and the lower motor neurons were not depleted; it remains unclear whether the tau aggregations of the lower motor neurons impaired muscle strength and ventilation. Prominent tau aggregation within the lower motor neurons has also been reported among patients with GGT, and those patients sometimes demonstrate motor neuron disease-like muscle weakness [8]. The limitation of this study is lack of comprehensive neurophysiological assessments including electromyography, respiratory monitoring, and polysomnography. Detailed assessments of the respiratory and autonomic systems could further reveal the pathomechanism of the various nonmotor symptoms of the patient.

Argyrophilic grains may contribute to atrophy and the presence of ballooned neurons in the medial temporal structures of our patient. Several studies have demonstrated patients with occasional diffuse AGD (DAGD) that involves not only the medial temporal lobes but also the neocortices, limbic cortices, and the brainstem [14, 22]. FTD-like behavioral disorders, mood disorders, or mild parkinsonism have been described in these patients [14, 22]. A recent study revealed that extensions of granular or fuzzy astrocytes were positively correlated with progression of AGD [23]. However, neuronal loss and neuronal and astrocytic tau aggregations in our patient were clearly broader than the presence of argyrophilic grains. The western blot of our patient exhibited a band in those molecular weights [23]. We consider that the clinicopathological phenotypes of our patient cannot be explained by AGD alone. A prominent tau aggregation in the brainstem or the spinal cord could be indicative of IgLON5-related tauopathy. However, this disease entity usually displays a combination of 3R and 4R-tauopathy [9]. Myotonic dystrophy is also associated with tauopathies but usually demonstrates 3R tauopathy or a combination of 3R and 4R tauopathies [5, 20, 25, 32]. In addition, skeletal muscle of our patient did not have pathologic features of myotonic dystrophy. Those facts differentiate our patient from IgLON5-related or myotonic dystrophy-related tauopathy, although assessments of HLA haplotypes or genetic analyses of DMPK and CNBP genes were not available. Neuronal aggregations of phosphorylated TDP-43 were influent but always colocalized with tau aggregations in our patient. The results of anti-p62 and anti-dipeptidyl immunohistochemistry and a C9orf72 gene analysis suggest that TDP-43 aggregation in our patient might be induced by 4R-tau aggregation [16] rather than primary TDP-43 proteinopathy.

In this report, we described a patient who was characterized by parkinsonism and progressive respiratory failure in association with unclassified 4R-tau aggregation. Our results further extend the clinical and neuropathologic spectra of 4R-tauopathy.

Abbreviations
4R-tau: four-repeat tau; 3R-tau: three-repeat tau; AGD: argyrophilic grain dementia; ARTAG: aging-related tau astrogliopathy; CA: cornu ammonis; CBD: corticobasal degeneration; ChAT: choline acetyltransferase; DCTN-1: dynactin subunit 1; DNA: deoxyribonucleic acid; FTD: frontotemporal dementia; GGT: globular glial tauopathy; MAPT: microtubule-associated protein tau; PD: Pick’s disease; PSEN-1: presenilin-1; PSP: progressive supranuclear palsy; TDP-43: TAR DNA binding protein 43 kDa; TH: tyrosine hydroxylase; TrOH: tryptophan hydroxylase; VLM nucleus: ventrolateral medullary nucleus.

Acknowledgements
We appreciate the patient’s family for providing tissue and genetic materials.

Authors’ contributions
Autopsy (A.A., M.H., and Y.I.), clinical analysis (M.N., Y.W., Y.A., A.T., K.H., A.Y., K.S., and M.T.), pathologic analysis (Y.R. and M.Y.), biochemical analysis (M.H.), genetic analysis (K.N., Y.L., H.Y., and N.H.), drafting manuscript (M.N.), and manuscript supervision (Y.R. and M.Y.). All authors read and approved the final manuscript.

Funding
The authors are very grateful for these grants: AMED-CREST (Japan Agency of Medical Research and Development), Practical Research Project for Rare/Intractable Diseases from AMED, 15ek01090290d020 (N.H.); AMED under grant numbers JP18dm0107105, 19dm0107105, and JP16kk0205009, and Grants-in-Aid from the Research Committee of CNS Degenerative Diseases, Research on Policy Planning and Evaluation for Rare and Intractable Diseases, Health, Labour and Welfare Sciences Research Grants, the Ministry of Health, Labour and Welfare, Japan (M.Y.).

Availability of data and materials
All clinical data and material from the pathology are available from Mari Yoshida (myoshida@aichi-med-u.ac.jp).

Ethics approval and consent to participate
This study is in compliance with the ethical committee for medical research of Aichi Medical University (committee acceptance number: AKBRC15-017).

Consent for publication
All authors agree with the submission of this manuscript to the designated journal.
Competing interests
We have no conflicts of interest to report.

Author details
1. Department of Neurology, National Center for Geriatrics and Gerontology, 7-430 Morioka, Obu, Aichi 474-8522, Japan. 2. Institute for Medical Science of Aging, Aichi Medical University, 1-1 Yazakokamitai, Nagakute, Aichi 480-1195, Japan. 3. Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113-8421, Japan. 4. Department of Brain and Neuroscience, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya, Tokyo 156-8506, Japan. 5. Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo, Tokyo 113-8421, Japan. 6. Department of Neurology, Nagoya University, 65 Tsuuma-cho, Nagoya, Aichi 466-8560, Japan.

References
1. Andreadi A, Brown WM, Kosik KS (1992) Structure and novel exons of the human tau gene. Biochemistry 31:10626–10633
2. Araki T, Ikeda K, Akijama H, Nonaka T, Hasegawa M, Ishiguro K et al (2004) Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 55:72–79
3. Arima K (2006) Ultrastructural characteristics of tau filaments in tauopathies: immunoelectron microscopic demonstration of tau filaments in tauopathies. Neuropathology. 26:475–483
4. Bigio EH, Lipton AM, Yen SH, Hutton ML, Baker M, Nacharaju P et al (2001) Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J Neuropathol Exp Neurol 60:328–341
5. Delacourte A, Buée L (2000) Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurobiol 13:371–376
6. Farrer MJ, Hulihan WM, Kachergus JM, Dächsel JC, Stoessl AJ, Grantier LL et al (2009) DCTN1 mutations in Perry syndrome. Nat Genet 41:163–165
7. Ferring I, Legati A, García-Monco JC, Gomez-Beldarrain M, Carmona M, Blanco R et al (2015) Familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy. J Neuropathol Exp Neurol 74:370–379
8. Fujita Y, Nishihira Y, Kurosawa S, Toyoshima Y, Ishihara T, Shinozaki M et al (2010) Sporadic four-repeat tauopathy with frontotemporal lobar degeneration, parkinsonism, and motor neuron disease: a distinct clinicopathological and biochemical disease entity. Acta Neuropathol 120:21–32
9. Gelpi E, Höffberger R, Graus F, Ling H, Holton JL, Dawson T et al (2018) Four-repeat tau dominant pathology in a congenital myotonic dystrophy type 1 patient with mental retardation. Brain Pathol 30:891–899
10. Gelpi E, Hoffberger R, Graus F, Ling H, Holton JL, Dawson T et al (2016) Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 132:531–543
11. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Clon-9. Gelpi E, Höftberger R, Graus F, Ling H, Holton JL, Dawson T et al (2016) Ulcer-investigated case with presenile onset. Neuropathopath 25:165–170
12. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H et al (1998) Autosomal dominant Alzheimer’s disease: linkage to chromosome 14 linked to MAPT N279K mutation in relation to tau positive emission tomography features. Mov Disord 13:586–574
13. Ichihara K, Araki S, Itoh N, Shiota J, Kawamura M, Yoshida M et al (2005) Argyrophilic grain disease presenting with frontotemporal dementia: a neuropathological and pathological study of an autopsied case with presenile onset. Neuropathol 25:165–170
14. Iwasaki Y, Mori K, Ito M, Tatsumi S, Mimuro M, Kuwano et al (2016) An autopsy described case of unclassifiable sporadic four-repeat tauopathy presenting with parkinsonism and speech disturbances. Neuropathology 36:295–304
15. Koga S, Sanchez-Contreras M, Josephs KA, Uitti RJ, Graff-Radford N, van Gerpen JA et al (2017) Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov Disord 32:246–255
16. Kovacs GG, Majtenyi K, Spina S, Murrell JR, Gelpi E, Höffberger R et al (2008) White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 67:963–975
17. Kovacs GG, Wörher A, Strobel T, Botond G, Attems J, Budka H (2011) Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. Clin Neuropathol 30:3–10
18. Kovacs GG, Xie SX, Lee EB, Robinson JL, Caswell C, Irwin DJ et al (2017) Multisite assessment of aging-related tau astroglialopathy (ARTAG). J Neuropathol Exp Neurol 76:605–619
19. Kuro S, Sakai M, Yoshida M, Mimuro M, Hashizume Y (2013) Neurofibrillary tangles in the peripheral sympathetic ganglia of patients with myotonic dystrophy. Neuropathol Appl Neurobiol 39:585–588
20. Mann DIA, Snowden JS (2017) Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol 27:723–736
21. Maurage CA, Sergeant N, Schraen-Maschke S, Lebert F, Ruchoux MM, Sablonnière B et al (2003) Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease. Acta Neuropathol 106:575–583
22. Miki T, Yokota O, Haraguchi T, Ishizu H, Hasegawa M, Ishihara T et al (2020) Factors associated with development and distribution of granular/fuzzy astrocytes in neurodegenerative diseases. Brain Pathol 30:891–899
23. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The consortium to establish a registry for alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486
24. Mizuno Y, Maeda N, Hamasaki H, Arahata H, Sasaogasako N, Honda H et al (2018) Four-repeat tau dominant pathology in a congenital myotonic dystrophy type 1 patient with mental retardation. Brain Pathol 34:441–443
25. Ohshima S, Tsuboi Y, Yamamoto A, Kawakami M, Farrer MJ, Kira J, Shii H (2010) Autonomic failures in Perry syndrome with DCTN1 mutation. Parkinsonism Relat Disord 16:612–614
26. Rendon AE, Majounie E, Waine A, Simón-Sánchez J, Rollinson S, Gibbs JR et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268
27. Rikuy Watanabe H, Mimuro M, Iwasaki Y, Ito M, Katsuno M et al (2017) Non-motor multiple system atrophy associated with sudden death: pathological observations of autonomic nuclei. J Neurol 264:2249–2257
28. Satoh Y, Ruberu NN, Sawabe M, Araki T, Tanaka N, Kukuta Y et al (2004) Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 63:911–918
29. Taniguchi-Watanabe S, Araki T, Katenmari T, Nonaka T, Masuda-Suzukake M, Tanatani A et al (2016) Biochemical classification of tauopathies by immuno-noblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and tsprin-resistant tau. Acta Neuropathol 131:267–280
30. Thai DR, Rub U, Grantes M, Brak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800
31. Vermersch P, Sergeant N, Ruchoux MM, Hofmann-radanyi HH, Wattiez A, Pett H et al (1996) Specific tau variants in the brains of patients with myotonic dystrophy. Neurology 41:479–486
32. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 41:479–486
33. Ion AmpliSeq Designer. https://www.ampliseq.com
34. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.